Prevention of deep wound infection in morbidly obese patients by infusion of an antibiotic into the subcutaneous space at the time of wound closure

Obesity Surgery
J Wesley Alexander, Rosemary Rahn

Abstract

Wound infections have been reported to occur in as many as 15% of wounds following the open procedure for gastric bypass in morbidly obese patients, resulting in significant disability, an increased health-care expenditure, and even death. This study was performed to assess the potential for reduction of wound infection in patients undergoing open gastric bypass by using a multimodal application of measures including infusion of an antibiotic (kanamycin) into the wound after closure and allowing it to dwell for 2 hours. Follow-up was for a minimum of 6 weeks. Of 400 consecutive evaluable patients, none had a wound infection which started in the subcutaneous fat or fascia. One patient had a stitch abscess, two had superficial infections secondary to wound separation after suture removal, and one had infection after spontaneous evacuation of a seroma. Using an infusion of kanamycin into the wound and allowing it to dwell for a 2-hour period, along with other standard preventive measures, eliminated primary deep subcutaneous and fascial wound infections after open gastric bypass procedures.

Citations

Mar 7, 2013·Surgical Infections·Dale W BratzlerUNKNOWN Society for Healthcare Epidemiology of America (SHEA)
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·S M McHughH Humphreys
Jun 7, 2015·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Patrick J ShabinoGuilherme M Campos
Aug 8, 2013·The Journal of Hospital Infection·R HuttunenJ Syrjänen
Apr 17, 2015·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Anna S van der HorstLaurence Dahners
Feb 18, 2011·Gynecologic Oncology·Elizabeth K NugentPremal H Thaker
Jan 24, 2007·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·J Wesley Alexander, Hope Goodman
Jun 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Teena ChopraKeith S Kaye
Feb 29, 2020·Surgical Infections·Álvaro A B FerrazCharles E Edmiston

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.